Oramed Pharmaceuticals
ORMP
17 hedge funds and large institutions have $3.37M invested in Oramed Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 10 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
23% less funds holding
Funds holding: 22 → 17 (-5)
40% less capital invested
Capital invested by funds: $5.61M → $3.37M (-$2.23M)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $102K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$57.2K |
| 2 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$8.05K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$5.77K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.67K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$4.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
-$2.88M |
| 2 |
D.E. Shaw & Co
New York
|
-$126K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$65K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$60.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$32K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| – | -$845 | -175 | Closed |
|
27
Citigroup
New York
| – | +$555 | +115 | New |
|
ORMP Hedge Fund Activity: Q1 2015 in Review
17 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2015, worth a combined $3.37M — down 40% from $5.61M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ORMP and 5 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $57.2K. The largest seller was Stifel Financial, exiting entirely with an estimated $2.88M sold.
- 17 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2015, down from 22 in Q4 2014.
- Funds reported $3.37M of Oramed Pharmaceuticals stock for Q1 2015, down 40% quarter-over-quarter.
- 5 funds opened new Oramed Pharmaceuticals positions in Q1 2015 and 10 closed out, a net change of -5 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2015 was Two Sigma Securities, an estimated $57.2K added.
- The largest Oramed Pharmaceuticals seller in Q1 2015 was Stifel Financial, an estimated $2.88M sold.
Based on aggregated 13F filings for Q1 2015.